CAMBRIDGE, UK – 4 May 2016 – MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that the company is scheduled to attend the following events:

(1) Mitochondrial Medicine: Developing New Treatments for Mitochondrial Disease conference, 4 – 6 May, Wellcome Genome Campus, Hinxton, Cambridge, UK

Michael Koslowski, Chief Medical Officer, to attend the conference

The conference will bring together world leaders in the field of translational mitochondrial medicine in an interactive program designed to engage and inspire a new generation of mitochondrial researchers, who will harness this new technology to prevent and treat these devastating diseases. The meeting attracts international delegates interested in mitochondrial diseases, working in molecular genetics, biochemistry, pathology, and clinical medicine.

(2) Bio€quity Europe, 10 – 11 May 2016, Scandic Hotel, Copenhagen, Denmark

Anker Lundemose, Chief Executive Officer, to present on Tuesday 10th May at 4.00 pm CET

David Luther, Chief Financial Officer, to attend the conference

Now in its 17th year, Bio€quity Europe is a major industry event for financial dealmakers looking for investor-validated life science companies and for pharmaceutical licensing professionals to assess top prospects. Bio€quity Europe has showcased more than 700 leading European companies to thousands of investment and pharma business development professionals. Delegates from over 20 nations attended the event last year.

(3) EMBO Conferences Cellular signalling and Cancer therapy, 27 – 31 May 2016, Hotel Croatia Cavtat, Dubrovnik, Croatia

The EMBO Conference brings together leading experts from different scientific disciplines to discuss new findings and future challenges in cancer research. The aim of this edition is to share new insights in our understanding of cancer and discuss how these insights provide new strategies for the development and improvement of diagnostic tools and cancer treatment.

For further events, please visit the MISSION Therapeutics website.

 

For more information, contact:

MISSION Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel +44 1223 497199

Hume Brophy

Mary Clark, Eva Haas, Hollie Vile

Email: missiontherapeutics@humebrophy.com

Tel: +44 (0) 20 7862 6390

 

NOTES TO EDITORS:

About MISSION Therapeutics

MISSION Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and non-malignant disease. It has built a world-leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.

DUBs are involved in multiple cellular processes, including DNA damage response and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs for treating cancer and other unmet medical needs, including neurodegenerative disease, muscle wasting and infectious disease. Despite significant efforts within the pharmaceutical sector, there is a lack of DUB inhibitors in clinical development.

MISSION’s leadership team has a wealth of international, commercial and scientific experience and the company has strong links with key academic and research centers including Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge. Professor Steve Jackson at Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge is the scientific founder of MISSION and is the Chief Scientific Officer of the Company.

MISSION Therapeutics has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. MISSION is based at the Babraham Research Campus, south of Cambridge

 CAMBRIDGE, UK – 1 March 2016 – MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that Anker Lundemose, Chief Executive Officer, and Dr Xavier Jacq, VP Scientific Affairs, are scheduled to present at the following events:

(1) 6^th Ubiquitin Research and Drug Discovery GTC Conference, 29 February-1 March, 2016, San Diego, CA

Dr Xavier Jacq, VP Scientific Affairs, to present on Tuesday, 1^st March 2016 at 11.25 am PST on “Discovery of highly selective DUB inhibitors with in vivo pre-clinical activity”

This conference provides a forum for researchers from both industry and academia to learn about recent advances in basic science and drugs that target the ubiquitin/proteasome system. Topics will include autophagy in cancer, developments with deubiquitinating enzymes, and novel drug targets in the ubiquitin system.

(2) Cowen and Company 36^th Annual Health Care Conference, 7-9 March 2016, The Boston Marriott Copley Place, Boston, Massachusetts

Anker Lundemose, CEO, to present on Tuesday, 8^th March 2016 at 3.30 pm EST

Cowen and Company’s conferences belong to major industry events and connects top institutional investors with leading companies in the healthcare sector.

(3) 9^th Annual European Life Science CEO Forum & Exhibition, 15-16 March 2016, Hilton Zurich Airport Hotel, Switzerland

Anker Lundemose, CEO, to speak on Tuesday, 15^th March 2016 at 2.00 pm CET on the panel “Platform Technologies & Novel Therapeutics Panel” as well as present an overview of MISSION therapeutics at 4.45 pm CET

The event brings together venture-funded and small-cap companies as well as leading investors, pharmas, and scientific thought leaders. The event includes sessions on Public Markets and M&A, Investment, Partnering as well as panels on: Clinical Development, Regulation in Europe, Innovation and BD&L in Oncology as well as Platform Technologies & Novel Therapeutics.

(4) Keystone Symposia on Molecular and Cellular Biology: Ubiquitin Signaling (X3), 13-17 March 2016, Whistler Conference Centre, Whistler, British Columbia, Canada

Dr Xavier Jacq, VP Scientific Affairs, to present on Monday, 14^th March 2016 at 5.00 pm PST on “Role of Ubiquitylation in Control of Autophagy, Short Talk: Inhibitors of USP30 as a Potential Treatment of Parkinson’s disease And Other Mitochondrial Dysfunctions”

Organized by Keystone Symposia on Molecular and Cellular Biology, the conference aims to connect the scientific community and accelerate life science discovery. The meeting will focus on how ubiquitylation controls processes such as autophagy, neurodegenerative diseases, hypertension and the immune system.

 

For more information:

 CONTACT:

 MISSION Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel +44 1223 497199

 Hume Brophy

Mary Clark, Eva Haas, Hollie Vile

Email: missiontherapeutics@humebrophy.com

Tel: +44 (0) 20 7862 6390

 

NOTES TO EDITORS:

About MISSION Therapeutics

MISSION Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and non-malignant disease. It has built a world-leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.

DUBs are involved in multiple cellular processes, including DNA damage response and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs for treating cancer and other unmet medical needs, including neurodegenerative disease, muscle wasting and infectious disease. Despite significant efforts within the pharmaceutical sector, there is a lack of DUB inhibitors in clinical development.

MISSION’s leadership team has a wealth of international, commercial and scientific experience and the company has strong links with key academic and research centers including Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge. Professor Steve Jackson at Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge is the scientific founder of MISSION and is the Chief Scientific Officer of the Company.

MISSION Therapeutics has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. MISSION is based at the Babraham Research Campus, south of Cambridge.

Expands management team with accomplished senior executive

CAMBRIDGE, UK – 1 October 2015 – MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating (DUB) enzymes to treat cancer and other diseases, announced the appointment of David Luther as Chief Financial Officer, to take effect from 1^st October 2015.

Mr Luther brings more than 25 years’ financial and operational experience, across the healthcare, FMCG and pharmaceutical industries. He joins MISSION from Spotless Group, a private equity backed FMCG business, having successfully supported them in a trade exit to Henkel. He served as VP Finance for commercial and supply chain operations in the UK, Ireland and Italy.

Prior to the Spotless Group, Mr Luther was Finance Director for the Italian operations of Aptuit, a global healthcare contract services organisation, and prior to this spent 15 years at GlaxoSmithKline (GSK). At GSK, Mr Luther held a number of senior roles, including Director, Corporate Development, responsible for M&A transactions, Finance Director Neurosciences, helping to create GSK’s innovative drug discovery concept, commercial Finance Director positions in Hungary and Poland, and initially as an Operations Consultant, performing consulting and compliance reviews across the organisation.

Mr Luther trained and qualified as an ACA with KPMG and has a BSc in Biochemistry from the University of Surrey. He has lived and worked in the UK, USA, Poland, Hungary, Italy and South Africa.

Commenting on the appointment, Dr Anker Lundemose, Chief Executive Officer of MISSION Therapeutics, said: “David’s financial acumen, extensive experience and exemplary track record in both large pharma and private equity-backed companies will be invaluable to MISSION. This welcome appointment comes at a pivotal moment in our corporate development and complements the senior management team as our assets grow with the success of our discovery programmes.”

David Luther, newly appointed Chief Financial Officer of MISSION Therapeutics, added: “I am very enthusiastic about joining the highly experienced MISSION management team and look forward to working with them and the Company’s investors to create and deliver value from the diverse therapeutic opportunities generated by the Company’s discovery platform.”

 

CONTACT:

MISSION Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel +44 1223 497454

 

Hume Brophy

Mary Clark, Eva Haas, Hollie Vile

Email: missiontherapeutics@humebrophy.com

Tel: +44 203 440 5654

 

NOTES TO EDITORS:

About MISSION Therapeutics

MISSION Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and other diseases of unmet need. It has built a World-leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.

MISSION’s leadership team has a wealth of international, commercial and scientific experience and the company has strong links with key academic and research centers including Cancer Research UK laboratories and the Jackson Laboratories at the Gurdon Institute, University of Cambridge.

The Company has received £27 million in venture capital from a blue chip syndicate comprising institutional (Sofinnova Partners, Imperial Innovations) and corporate (SR One, Roche Venture Fund and Pfizer) investors, and was awarded a £1.9 million grant from Innovate UK in September 2015. MISSION is based at the Babraham Research Campus, south of Cambridge.

CAMBRIDGE, UK – 1 September 2015 – MISSION Therapeutics (MISSION), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer and other diseases, today announced the appointment of Dr Michael Koslowski as Chief Medical Officer to take effect from 1 September 2015.

Dr Koslowski brings over 15 years’ experience across biopharmaceutical research and development, specialising in drug target discovery and clinical validation. Dr Koslowski joins MISSION from Glenmark Pharmaceuticals where he served as Head of Clinical Sciences & Early Development and led Glenmark’s first oncology development programme. Prior to this, Dr Koslowski was Global Head of Translational Medicine Experts at Boehringer Ingelheim, where he had oversight of the transition of projects and programmes across all therapeutic areas, from early research through to clinical proof of concept.

Commenting on the appointment, Dr Anker Lundemose, Chief Executive Officer of MISSION Therapeutics, said: “We are very pleased to welcome Dr Koslowski to MISSION’s senior management team. His track record and expertise in successfully translating research into the clinic will enable us to further advance our proprietary DUB platform, and develop new classes of medicines in cancer as well as other disease areas with high unmet medical need. This appointment supports MISSION’s growth strategy as we continue to transition our business into a clinical stage organisation. We look forward to benefiting from Dr Koslowski’s experience and in-depth knowledge of clinical development.”

Dr Michael Koslowski, newly appointed Chief Medical Officer of MISSION Therapeutics, added: “MISSION has developed a proprietary and world-class technological and transferable expertise in developing DUB inhibitors. I am thrilled to join this highly experienced team in progressing the potential of the Company’s platform.”

Prior to Boehringer Ingelheim, Dr Koslowski was Associate Professor of Molecular Medicine at the University of Mainz. He is also founding member and former Group Head, New Targets & Antibody Development, Ganymed Pharmaceuticals AG, a spin-off from the Universities of Mainz and Zürich. While at Ganymed Pharmaceuticals AG, Dr Koslowski implemented a sustainable target discovery platform, one of the cornerstones for the foundation of the Company. Dr Koslowski was Principal Scientist in Experimental and Translational Oncology at the University of Mainz from 2000 to 2010, and a research scientist in Target Discovery and Research at University of the Saarland in Hamburg.

CONTACT:

MISSION Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel +44 1223 497454

Hume Brophy

Mary Clark, Eva Haas, Hollie Vile

Email: missiontherapeutics@humebrophy.com

Tel: +44 203 440 5654

NOTES TO EDITORS:

About MISSION Therapeutics

MISSION Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and other diseases of unmet need. It has built a World-leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.

MISSION’s leadership team has a wealth of international, commercial and scientific experience and the Company has strong links with key academic and research centres including Cancer Research UK laboratories and the Jackson Laboratories at the Gurdon Institute, University of Cambridge.

The Company has received £27 million in venture capital from a blue chip syndicate comprising institutional (Sofinnova Partners, Imperial Innovations) and corporate (SR One, Roche Venture Fund and Pfizer) investors and is based at the Babraham Research Campus, south of Cambridge.

Professor Steve Jackson, MISSION Therapeutics CSO and Professor of Biology, Head of Cancer Research UK laboratories at the Gurdon Institute, University of Cambridge, will be giving the 22nd Raymond and Beverly Sackler distinguished lecture on the 11th of June in Leeds and on the 25th of June in Cambridge. The title of the lecture is ‘Cellular responses to DNA damage:mechanistic insights and new cancer therapies’.